eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
1/2023
vol. 25
 
Share:
Send email
Share:
abstract:
Review paper

Poly(Ethylene Glycol)-Poly(Lactic Acid) TLR7 Agonist as a Novel HBsAg Immune Response Stimulant

Bryan Gervais de Liyis
1
,
David Christopher Tjandra
1
,
Viona Mareska
1
,
Jane Carissa Sutedja
1
,
Cokorda Agung Wahyu Purnamasidhi
2
,
Cokorde Istri Yuliandari Krisnawadani K.
2

  1. Faculty of Medicine, Udayana University, Bali, Indonesia
  2. Department of Internal Medicine, Faculty of Medicine, Udayana University/ Udayana University Hospital, Bali, Indonesia
Family Medicine & Primary Care Review 2023; 25(1): 87–92
DOI: https://doi.org/10.5114/fmpcr.2023.125499
Online publish date: 2023/03/31
View full text Get citation
 
PlumX metrics:
Hepatitis B is caused by a hepatitis B virus infection, causing inflammation of the liver. The therapeutic approach used to help treat HBV infection has been based on re-establishing a functioning T cell response and limiting additional negative consequences. Due to inadequate outcomes, new strategies for enhancing the immune response and inducing a particular HBV immune response have been developed. Activation of toll-like receptor 7 plays a role in mediating the immune response. TLR7 has shown to increase T cell activity, increase production of cytokines, increase the number of NK cells and lower serum concentrations of HBsAg, thus showing high potential to prevent and treat chronic hepatitis B. Evaluation of NK cell cytokine generation and degranu-lation reveals a considerable improvement in every cell function when compared to baseline values. However, TLR agonists are microscopic molecules that are rapidly eliminated from the system following ingestion and may cause significant systemic adverse effects. Poly(Ethylene Glycol)-Poly(Lactic Acid) can be utilised to increase the effectiveness of the toll-like receptor 7 agonist and lower the negative effects of the TLR7 agonist. TLR7 agonist distribution may be enhanced by an effective drug carrier, and conjugating a macromolecule may increase pharmacokinetics without toxicity or other negative side effects. The Poly(Ethylene Glycol)-Poly(Lactic Acid) TLR 7 agonist is potentially beneficial in treating hepatitis B as an immune response stimulant.
keywords:

Hepatitis B, immunity, TLR7 agonist

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.